Authors

Hawaii Reaches Settlement With Plavix Makers Over Deceptive Labeling

Hawaii has secured a $700 million settlement with the manufacturers of Plavix following a lawsuit alleging they concealed for years the drug's ineffectiveness and potential danger for individuals of East Asian or Pacific Islander descent, a risk that the FDA later required to be disclosed with a boxed warning.

The Evolving Role of Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

The Pharmacist’s Role in Evaluating 505(b)(2) Drugs

Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.

Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes

New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and adverse effects.

Pharmacists Can Advance Immunomodulatory Care in Multiple Myeloma

Pharmacists can play a pivotal role in overcoming the many challenges that exist in accessing immunomodulatory drugs in multiple myeloma.

Navigating Prescription Stimulant Use: Safety, Legal, and Supply Challenges in Pharmacy Practice

The rising use of prescription stimulants in the US presents significant safety risks, legal challenges, and supply chain shortages, emphasizing the need for pharmacist involvement in promoting responsible prescribing.

Why Modest Trial Gains Aren’t Enough: The Case for Value-Driven Drug Approval

Patients need evidence that reflects real benefit.

Neuriva: A Closer Look at the Efficacy and Safety of this Popular Supplement

Biosimilar Adoption: The Pharmacist's Role in Formulary Decisions, Patient Counseling, and Safe Use

Biosimilars lower biologic costs and widen access.

Bridging the Gap: Field Teams and Hubs Supporting Patient Care

Enhanced communication between field representatives and case managers improves medication access for patients with rare diseases.

Low-Dose Lithium Shows Promise for Mild Cognitive Impairment

Neurology trial tests low-dose lithium for MCI and Alzheimer risk; results miss primary end points but hint at slower verbal memory decline.

Pharmacist-Led BiTE Program at a Community Cancer Center

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Hormone Replacement Therapy for Menopause: Revisiting Evidence and Looking Ahead

Reevaluating menopause hormone therapy myths, risks, timing, and access.

Interprofessional Education in Medical School Creates a Collaborative Environment

Adaptability, teamwork, and a culture of lifetime learning are required virtues in our rapidly evolving medical landscape.

The Future of Cancer Drug Development: Advancements, Challenges, and the Transformative Role of AI

AI is revolutionizing oncology drug development, enhancing therapeutic identification and reducing approval times, but use of this tool must be carefully implemented to mitigate risks and ensure regulatory compliance.

Advancing the Role of Pharmacy Technicians in Hazardous Drug Compounding

Pharmacy technicians enhance safety and efficiency in hazardous drug compounding.

Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.

Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

Rebalancing Reproductive Responsibility: Progress in Nonhormonal Male Contraception

Male contraceptives represent a step toward equality in reproductive responsibility.

Cetirizine and Levocetirizine Withdrawal Pruritus: What Pharmacists Need to Know About the FDA’s New Safety Warning

The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.

Updated Clinical Guidelines Outline Optimal Treatment of Helicobacter pylori Infection

For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.

Standardizing Supplement Recommendations in a Neuro-Oncology Clinic: A Pharmacist-Led Quality Improvement Initiative

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Managing Sustainable Drug Spend: 5 Trends Reshaping Pharmacy Benefits in 2025

The US health care market faces transformative changes in 2025, as biosimilars, GLP-1s, and new pharmacy economics reshape how benefit managers balance innovation with affordability.

Understanding Dermatologic Care in Skin of Color: Limitations in Education and Research, Clinical Considerations, and Patient Counseling

Dermatology care for skin of color can be improved by understanding inflammation-driven hyperpigmentation, safer treatments, and addressing education gaps that delay diagnosis and worsen outcomes.

Op-Ed: True PBM Transformation Starts with Pharmacists

Clinical pharmacists reshape PBMs with medication optimization, cutting drug spend and improving outcomes through smarter, safer prescribing.

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

The Hidden Impact of Pharmacy Supply Chain Disruption on Patient Care  

Pharmacy supply chain disruptions directly shape the treatment that patients receive, making it vital that pharmacists understand the causes and consequences of delays.